FBL and rheumatoid arthritis: To evaluate potential clinical interest in ACa-Fib IgG from 184 RA patients of the VErA cohort who met the 2010 ACR/EULAR criteria, three follow-up time-points were considered, i.e., baseline (M0), 6 months (M6), and 2 years (M24).